Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
Rascol
O
O
Clinical Pharmacological Laboratory, University Hospital, Toulouse, France.
Brefel-Courbon
C
C
Descombes
S
S
Montastruc
J L
JL
D000978:Antiparkinson Agents / Q000009:adverse effects*; D015259:Dopamine Agents / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D017447:Receptors, Dopamine D1 / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D007980:Levodopa